Bioanalytical considerations in the comparability assessment of biotherapeutics.
about
Specific method validation and sample analysis approaches for biocomparability studies of denosumab addressing method and manufacture site changesA novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines.A generic template for automated bioanalytical ligand-binding assays using modular robotic scripts in support of discovery biotherapeutic programs.Validation and life-cycle management of a quantitative ligand-binding assay for the measurement of Nulojix(®), a CTLA-4-Fc fusion protein, in renal and liver transplant patients.
P2860
Bioanalytical considerations in the comparability assessment of biotherapeutics.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Bioanalytical considerations in the comparability assessment of biotherapeutics.
@en
Bioanalytical considerations in the comparability assessment of biotherapeutics.
@nl
type
label
Bioanalytical considerations in the comparability assessment of biotherapeutics.
@en
Bioanalytical considerations in the comparability assessment of biotherapeutics.
@nl
prefLabel
Bioanalytical considerations in the comparability assessment of biotherapeutics.
@en
Bioanalytical considerations in the comparability assessment of biotherapeutics.
@nl
P2093
P2860
P356
P1433
P1476
Bioanalytical considerations in the comparability assessment of biotherapeutics.
@en
P2093
Binodh DeSilva
Jean W Lee
Michael Moxness
Yow-Ming Wang
P2860
P304
P356
10.4155/BIO.11.25
P577
2011-03-01T00:00:00Z